<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758416</url>
  </required_header>
  <id_info>
    <org_study_id>STANDPOINT</org_study_id>
    <nct_id>NCT04758416</nct_id>
  </id_info>
  <brief_title>Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II, Single-center STudy on the vAlue of Non-invasive Dual-Pet（18F-FES PET and 68Ga-HER2-Affibody PET）InformatiOn IN Subtype of Metastatic Breast Cancer(MBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study on the Value of Non-invasive Dual-Pet(18F-FES PET and 68Ga-HER2-Affibody PET)&#xD;
      Information in Subtype of Metastatic Breast Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II, Single-center STudy on the vAlue of Non-invasive Dual-Pet（18F-FES PET and&#xD;
      68Ga-HER2-Affibody PET）InformatiOn IN Subtype of Metastatic Breast Cancer(MBC)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Verify the subtype value of dual-PET in extrahepatic metastases</measure>
    <time_frame>2 year</time_frame>
    <description>Verify whether the subtype value of FES-PET and HER2-PET is consistent with biopsy or surgical pathology in extrahepatic metastases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verify the HER2-PET value in liver metastasis</measure>
    <time_frame>2 year</time_frame>
    <description>Verify whether the HER2-PET value is consistent with biopsy or surgical pathology in liver metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verify the HER2-PET value in brain metastasis</measure>
    <time_frame>2 year</time_frame>
    <description>Verify whether the HER2-PET value is consistent with biopsy or surgical pathology in brian metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heterogeneity in metastatic lesions</measure>
    <time_frame>2 year</time_frame>
    <description>Observe the heterogeneity of ER and HER2 expression in metastatic lesions.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Metastatic breast cancer patients</arm_group_label>
    <description>50 metastatic breast cancer patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy or surgical pathology in metastases</intervention_name>
    <description>biopsy or surgical pathology in extrahepatic/liver/brain metastases</description>
    <arm_group_label>Metastatic breast cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-HER2 affibody,18F-FDG, 18F-FES</intervention_name>
    <description>68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.</description>
    <arm_group_label>Metastatic breast cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        50 metastatic breast cancer patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects voluntarily joined the study, signed informed consent, and had good&#xD;
             compliance.&#xD;
&#xD;
          2. Female patients aged over 18 years (including cutoff value).&#xD;
&#xD;
          3. an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          4. Recurrence or metastatic breast cancer confirmed by histopathology, or expect to be&#xD;
             feasible metastasis puncture or surgery to confirm histopathological recurrence or&#xD;
             metastatic breast cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or lactation.&#xD;
&#xD;
          2. Alcohol allergy is not suitable for FES-PET/ C.&#xD;
&#xD;
          3. There are contraindications for patients who are expected to have metastasis puncture&#xD;
             or surgery.&#xD;
&#xD;
          4. Mental disorders or other conditions affecting patient compliance.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <phone>64175590</phone>
    <phone_ext>5006</phone_ext>
    <email>huxicun@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Zhang, M.D.</last_name>
    <phone>64175590</phone>
    <phone_ext>85000</phone_ext>
    <email>syner2000@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Cancer Center Institutional Review Board</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xichun Hu, MD, PhD</last_name>
      <phone>64175590</phone>
      <phone_ext>5006</phone_ext>
      <email>huxicun@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 14, 2021</study_first_submitted>
  <study_first_submitted_qc>February 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Director of department of medical oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

